BioSpace News Archive

OcuTerra Therapeutics, Inc. today announced the company’s participation in two upcoming investor conferences.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the publication of preclinical research on the androgenetic alopecia (hair loss) treatment program, OLX104C, in Molecular Pharmaceutics.

Lantern Pharma Inc. today announced that it presented positive preclinical data on the efficacy of its drug candidate LP-184 for glioblastoma (GBM), used alone or in combination with the Food and Drug Administration (FDA) approved agent spironolactone, at the Society for Neuro-Oncology (SNO) annual meeting.

Generate Biomedicines today announced that Daria Hazuda, Ph.D., has been named Head of Vaccines and Infectious Disease Research and Lisa Wyman has been named Senior Vice President of Technical Operations.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced several key leadership changes.

Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the Piper Sandler Annual Healthcare Conference on Tuesday, November 29, 2022, at 10:00 AM ET in New York.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences.

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sander Healthcare Conference at 3:30 p.m. ET on Wednesday, November 30, 2022.

Theravance Biopharma, Inc. announced the final results of its Dutch auction tender offer to purchase up to $95 million of its ordinary shares, par value $0.00001 per share, which expired at midnight, New York City time, at the end of the day on November 17, 2022.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®.